The latest content updates from the drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ http://www.drugdevelopment-technology.com/content/images/logo_big.gif http://www.drugdevelopment-technology.com/projects/boostrix-vaccine-whooping-cough-tetanus-diphtheria/ http://www.drugdevelopment-technology.com/projects/boostrix-vaccine-whooping-cough-tetanus-diphtheria/ Boostrix is a three-in-one vaccine administered to protect against whooping cough, tetanus and diphtheria. Vaccination is an effective way to protect against them. Mon, 21 May 2012 23:30:00 GMT http://www.drugdevelopment-technology.com/news/newsperegrine-data-bavituximab-study http://www.drugdevelopment-technology.com/news/newsperegrine-data-bavituximab-study Peregrine Pharmaceuticals has announced positive results from its randomised, double-blind, placebo-controlled Phase 2b trial investigating two dose levels of bavituximab plus docetaxel versus docetaxel plus placebo in patients with second-line, non-… Mon, 21 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsipsen-active-biotech-tasquinimod-study http://www.drugdevelopment-technology.com/news/newsipsen-active-biotech-tasquinimod-study Active Biotech and Ipsen have announced that 600 patients have been recruited in the global, pivotal, randomised, double-blind, placebo-controlled Phase 3 study of tasquinimod, used to treat patients with metastatic castrate-resistant prostate cancer… Mon, 21 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newslubiprostone-reduce-pain-ibs-c-patients http://www.drugdevelopment-technology.com/news/newslubiprostone-reduce-pain-ibs-c-patients Sucampo Pharmaceuticals has announced the pooled data from post-hoc analyses of the two pivotal Phase 3 studies of Amitiza (lubiprostone), used for the treatment of irritable bowel syndrome with constipation (IBS-C). Sun, 20 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newstokai-positive-galeterone-data-study http://www.drugdevelopment-technology.com/news/newstokai-positive-galeterone-data-study Tokai Pharmaceuticals has reported additional data from a Phase 1 safety and proof-of-concept study investigating galeterone (TOK-001), in patients with castration-resistant prostate cancer (CRPC). Sun, 20 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsnucynta-er-tablets-show-efficacy-in-pain-management http://www.drugdevelopment-technology.com/news/newsnucynta-er-tablets-show-efficacy-in-pain-management Janssen Pharmaceuticals' Nucynta (tapentadol) extended-release (ER) tablets have been found effective in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neurophysiology (DPN) compared to placebo. Thu, 17 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newspositive-results-elevation-ep-101-copd http://www.drugdevelopment-technology.com/news/newspositive-results-elevation-ep-101-copd Elevation Pharmaceuticals has announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising chronic bronchitis and emphysema. Thu, 17 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/features/featureprogrammable-nanoparticles-future-cancer-treatment/ http://www.drugdevelopment-technology.com/features/featureprogrammable-nanoparticles-future-cancer-treatment/ Most cancer drugs are not as effective as doctors would like them to be because the amount that can be administered is limited by toxicity. But a new technology, Accurin, which utilises programmable nanoparticles, is set to change all that. Elly Earl… Thu, 17 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newstivozanib-superior-pfs-phase-3-study http://www.drugdevelopment-technology.com/news/newstivozanib-superior-pfs-phase-3-study Aveo Oncology and Astellas Pharma have announced positive findings from the Tivozanib Versus Sorafenib in 1st line Advanced RCC (TIVO-1) study of its investigational agent tivozanib. Wed, 16 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/projects/sutent-sunitinib-malate-treatment-pancreatic-neuroendocrine-tumours/ http://www.drugdevelopment-technology.com/projects/sutent-sunitinib-malate-treatment-pancreatic-neuroendocrine-tumours/ Sutent (sunitinib malate) is an oral multikinase inhibitor which is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumours (NET). Wed, 16 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsachaogen-plazomicin-meets-study-endpoints http://www.drugdevelopment-technology.com/news/newsachaogen-plazomicin-meets-study-endpoints Achaogen's plazomicin (ACHN-490) drug has met all the objectives in the multinational Phase 2 study conducted in adults with complicated urinary tract infections (cUTI) and acute pyelonephritis. Wed, 16 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/contractors/regulatory-affairs/mccarthy-consultant-services/ http://www.drugdevelopment-technology.com/contractors/regulatory-affairs/mccarthy-consultant-services/ McCarthy Consultant Services Inc. (MCSI) provides expert regulatory affairs consulting. As a global industry leader, MCSI understands the importance of sound regulatory management and client satisfaction. Wed, 16 May 2012 14:59:00 GMT http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus---issue-13/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus---issue-13/ From advances in robotic research to new cures for addictions and life-threatening diseases, drug developers are opening up new frontiers. Wed, 16 May 2012 09:39:00 GMT http://www.drugdevelopment-technology.com/news/newsgalectin-study-of-gm-ct-01-combination-therapy http://www.drugdevelopment-technology.com/news/newsgalectin-study-of-gm-ct-01-combination-therapy Galectin Therapeutics has dosed the first patient in a Phase 1/2 trial demonstrating the safety and efficacy of its carbohydrate-based galectin inhibitor compound, GM-CT-01, in combination with a Ludwig Institute peptide vaccine for treating advanced… Tue, 15 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsscil-ono-drug-discovery http://www.drugdevelopment-technology.com/news/newsscil-ono-drug-discovery Germany-based biotech company, Scil Proteins, has entered into a joint collaboration agreement with Japan's Ono Pharmaceutical for the discovery and development of new Affilin therapeutics to treat various diseases. Tue, 15 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsgalapagos-commences-phase-2a-study-of-glpg0634 http://www.drugdevelopment-technology.com/news/newsgalapagos-commences-phase-2a-study-of-glpg0634 Galapagos has begun the second Phase 2a clinical study of GLPG0634, a Janus kinase 1 (JAK1) inhibitor being developed to treat multiple autoimmune diseases, such as rheumatoid arthritis (RA). Mon, 14 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsdiltiazem-hydrochloride-improvement http://www.drugdevelopment-technology.com/news/newsdiltiazem-hydrochloride-improvement Ventrus Biosciences has reported positive data from a Phase 3 study treating patients suffering from anal fissures with its diltiazem hydrochloride cream (VEN 307). Mon, 14 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/projects/dulera-treatment-asthma/ http://www.drugdevelopment-technology.com/projects/dulera-treatment-asthma/ Dulera (mometasone furoate and formoterol fumarate dihydrate) is a new fixed-dose combination inhaler for the treatment of asthma. Sun, 13 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newscytochroma-ctap101-show-efficacy http://www.drugdevelopment-technology.com/news/newscytochroma-ctap101-show-efficacy Cytochroma has announced the positive results from the Phase 2b clinical trial of its drug product, CTAP101 capsules, used for the treatment of patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin … Sun, 13 May 2012 23:00:00 GMT http://www.drugdevelopment-technology.com/news/newsonconova-drug-phase-ii-study http://www.drugdevelopment-technology.com/news/newsonconova-drug-phase-ii-study Onconova Therapeutics has announced that it is advancing the oral formulation of rigosertib (Estybon, ON 01910.Na), an anti-cancer agent, into a new Phase 2 study. Sun, 13 May 2012 23:00:00 GMT